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Relevance 
 
Cardiovascular disease kills 1 in 3 people.  Every 3 minutes someone in the UK has 
a heart attack and 30% of these are fatal . Globally, around 17 million people die 
from cardiovascular disease each year. In 2010, the total costs of cardiovascular 
disease in the USA  was $444 billion and this number is predicted to increase to 
800 billion dollars by 2030. In the UK, according to the British Heart Foundation, 
the annual costs to the nation of premature death, lost productivity, hospital 
treatment and prescriptions relating to cardiovascular disease is of the order of £19 
billion.  Therefore, there is no question that cardiovascular dysfunction is a vast 
problem imposing a significant burden on every country’s health and wealth (1). 
 
It is widely accepted that our genes interact with traditional lifestyle factors, such 
as smoking, obesity and/or a sedentary lifestyle to promote an increased risk of 
heart disease (2).  It has also become established that the gene-environment 
interaction early in life may be just as, if not more, important in ‘programming’ 
heart health and heart disease (3).  This is unsurprising because our physiology is 
much more plastic and malleable during early life and the younger we are, the 
greater the impact the environment has upon us (3).  These concepts have brought 
attention to adverse pregnancy and whether it can increase the risk of 
cardiovascular disease in the offspring.  Accordingly, we now know that fetal 
development during suboptimal conditions can indeed trigger a fetal origin of 
cardiovascular dysfunction and increase the risk of chronic heart disease in the 
offspring in later life (3-5).   
 
One of the most common adverse intrauterine conditions in complicated pregnancy 
is chronic fetal hypoxia (4-6).  However, the contribution of chronic fetal hypoxia in 
promoting intrauterine growth restriction (IUGR) and programmed cardiovascular 
risk has been difficult to isolate for a number of reasons. For instance, it is 
established that high altitude pregnancy leads to IUGR (5). However, most high 
altitude populations are impoverished with significant maternal malnutrition (5). 
Therefore, the contribution of chronic fetal hypoxia versus chronic fetal 
undernutrition in slowing fetal growth and in setting future cardiovascular risk 
under these conditions is uncertain. The same applies to sea level pregnancy 
complicated by preeclampsia, placental insufficiency, gestational diabetes and even 
maternal obesity. All these conditions are associated with an increase in placental 
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vascular resistance (see 6), which will decrease oxygen as well as nutrient delivery 
to the growing fetus. This makes it impossible to disentangle the effects of chronic 
hypoxia versus chronic fetal undernutrition in promoting IUGR and programming of 
cardiovascular disease in human complicated pregnancy at sea level. Similarly, 
several experimantal studies including our own in mammalian animal models have 
shown that maternal chronic hypoxia during pregnancy can lead to IUGR and 
programme increased cardiovascular risk in the offspring (5,7). However, because 
experimental induction of chronic hypoxia in rodents can reduce maternal food 
intake and/or alter the quality of the maternal milk (5,7), the contribution of 
chronic fetal hypoxia versus chronic fetal and/or neonatal under-nutrition under 
these conditions, again, remains uncertain.  
 
Innovation 
 
By combining the chick embryo model with incubation at high altitude, this PhD 
thesis has been able to isolate the direct effects of chronic hypoxia due to high 
altitude on fetal growth, cardiovascular development, effects on the fetal stress axes 
and on the developmental programming of systemic and pulmonary vascular 
disease in the offspring.  This is because in contrast to mammals, with the 
exception of monotremes, in the chicken the effects of changes in oxygenation on 
the embryo can be isolated and determined directly, independent of effects of 
chronic hypoxia on maternal food intake or the qulity of the maternal milk for 
lactation. In addition, chickens have a short incubation period (21 days), meaning 
embryonic studies can be conducted quickly.  Maternal lives do not have to be 
taken in order to study the fetus and so for a fetal study the use of chickens could 
be described as more ethical, reducing the number of animal use, thereby 
complying with the 3R principle enshrined by the Home Office. The relatively large 
size of the chicken embryo at term (> 25g on day 19, term is 21 days) compared to 
the rodent fetus (< 4 g on day 20, term is 21 days) means that the chicken embryo 
model has the added advantage of facilitating study of cardiovascular function in 
ovo or in isolated organs, for instance by using the Langendorff preparation or the 
myograph (8). Interestingly, and perhaps surprisingly, the chronology of cardiac 
development in the chicken is much more comparable to the human than is the 
rodent, in which cardiac development continues into the postnatal period (8). 
Rodents are also polytocous, and the physiology of multiple pregnancies can be 
quite different to singletons, with different adaptations in place to support more 
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than one fetus (8). Combined, these advantages make the chicken embryo an 
animal model to isolate the effects of chronic hypoxia on cardiovascular 
development and programming of cardiovascular dysfunction. 
 
The data provided by the chicken studies performed in this thesis adds 
considerably to the existing body of literature to demonstrate that chronic fetal 
hypoxia can programme a developmental origin of cardiovascular disease 
independent of any effects of undernutrition. This is important because of the 
similarities between the patterns of cardiovascular disease in hypoxic animals and 
the cardiovascular disease found in human offspring of complicated pregnancy. For 
example, IUGR human fetuses and neonates show decreased cardiac ejection force, 
diastolic dysfunction, decreased cardiomyocyte numbers, hypertrophic hearts and 
increased aortic stiffness (8-10). Some factors, including aortic stiffness and 
endothelial dysfunction have also been reported to be more prevalent in adults who 
were growth restricted as fetuses (11). Whilst IUGR is not necessarily caused by 
chronic fetal hypoxia alone, the fact that animal models which isolate the effects of 
chronic hypoxia produce similar phenotypes confirms that chronic fetal hypoxia is 
likely to be an important factor in the correlations between complicated human 
pregnancy, IUGR and an increased risk of cardiovascular disease later in life. 
 
Target groups 
 
This sound knowledge base generated in this PhD study has the potential to 
significantly facilitate the national and international development of the field, 
providing a significant academic advance within the field and between related 
disciplines. The PhD candidate and supervisors attend national and international 
scientific meetings routinely and are deeply involved in undergraduate and 
graduate teaching. Therefore, we will refer to this PhD project at least at three 
levels: 1) at international and national scientific meetings; 2) in laboratory meetings 
to postgraduate and graduate students and technicians, and 3) in lectures to 
undergraduate students, especially those in their final year who may be 
contemplating potential PhD research projects.  It is important that investment is 
made to train new researchers, particularly in the vulnerable skills of fetal surgery 
and studying fetal cardiovascular function. To deliver maximum benefit in 
development of skills, capacity and capability, this PhD work will also serve as the 
basis to: 1) Provide cross-disciplinary training for emerging scientists in all 
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components of the thesis, spanning in vivo cardiovascular experimentation and 
stereological and histological analyses of the cardiovascular system; 2) Ensure that 
other scientists worldwide are exposed to the expertise available through 
international communications at scientific meetings; 3) Ensure that other scientists 
at the University of Cambridge, University of Maatricht and The Bolivian Institute 
for High Altitude Biology (IBBA) are exposed to the expertise available through 
maintained international collaboration.  Thereore, this PhD also serves in outreach 
programmes.   
 
The sound knowledge base generated in this PhD has also been published in high 
impact journals as original research articles.  Combinations of original articles have 
been further disseminated in Topical Reviews and letters to the Editor of high 
impact journals.  To further achieve excellence with impact, the University 
Communications Office at Cambridge has been alerted of the potential influence for 
human health of the scientific findings. Therefore, the work has had an immediate 
impact on clinicians, basic scientists, healthcare professionals, expectant mothers 
and their families in terms of providing them with information on the effects on the 
health of the offspring of high altitude pregnancy or reductions in fetal oxygenation 
in sea level complicated pregnancy.  In addition, the data will benefit the design of 
therapeutic strategies to protect pregnancy complicated by chronic fetal hypoxia 
and/or improve fetal growth and development in adverse pregnancy with drugs that 
limit the adverse effects of fetal hypoxia, such as with spcific antioxidants.  The 
proposed research is therefore likely to be of significant interest and benefit not only 
to researchers carrying out similar or related research in the field, but also to 
national and international researchers in other disciplines, such as experts in the 
metabolic syndrome, diabetes and gestational diabetes, scientists in biochemistry, 
pharmacology and nanotechnology, as well as cross-disciplinary teams in the 
pharmaceutical industry.  Therefore, the data generated directly and indirectly has 
the potential to reduce the burden of cardiovascular disease throughout the life 
course, thereby having a major clinical, economic and societal impact on health. 
 
Conclusion 
 
It is now established that adverse conditions during pregnancy can trigger a fetal 
origin of cardiovascular dysfunction and/or increase the risk of heart disease in 
later life.  Sub-optimal environmental conditions during early life that may promote 
 
103 
the development of cardiovascular dysfunction in the offspring include alterations 
in fetal oxygenation and nutrition as well as fetal exposure to stress hormones, 
such as glucocorticoids.  There has been growing interest in identifying the partial 
contributions of each of these stressors to programming of cardiovascular 
dysfunction.  However, in humans and in many animal models this is difficult, as 
the challenges cannot be disentangled.  By using the chicken embryo as an animal 
model and intertwining this with high altitude incubation, this PhD has been able 
to circumvent a number of problems.  The work has isolated an important direct 
contribution of chronic fetal hypoxia in regulating fetal growth, cardiovascular and 
endocrine development as well as in the programming of systemic and pulmonray 
vascular disease in the adult offspring. 
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